Supernus Pharmaceuticals (SUPN) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Supernus Pharmaceuticals published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• These are the last stand-alone results of Supernus Pharmaceuticals. On November 2, 2026 it became a wholly owned subsidiary of Indivior Pharmaceuticals, which renamed itself Supernus, Inc. and began trading under SUPN; each Supernus share was converted into 1.5401 Indivior shares.
• Supernus reports product revenue in millions to one decimal in its release, so the segment rows sum to $226.8 million against total revenues of $226.8 million.

Source: Supernus Pharmaceuticals Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Supernus Pharmaceuticals splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Supernus Pharmaceuticals's Total net product sales revenue was $179 million in Q3 2026, up 6% from $169 million in Q3 2025, 79% of total revenue.
• Supernus Pharmaceuticals's Collaboration revenue (ZURZUVAE) revenue was $41.7 million in Q3 2026, up 106% from $20.2 million in Q3 2025, 18% of total revenue.
• Supernus Pharmaceuticals's Royalty, licensing and other revenues revenue was $6.5 million in Q3 2026, up 91% from $3.4 million in Q3 2025, 3% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Supernus gave its stand-alone outlook as a table: 2026 total revenues of $875 million to $900 million (previously $860 million to $890 million), including ONAPGO net sales of $60 million to $65 million and Trokendi XR and Oxtellar XR net sales of $60 million to $67 million; GAAP operating loss of $5 million to $40 million; and adjusted operating earnings of $160 million to $180 million. The merger with Indivior closed on November 2, 2026, so this outlook no longer applies.

In its Q3 2026 release, Supernus Pharmaceuticals said:

“As a stand-alone company, the Company is raising its guidance for the full year 2026 financial guidance as set forth below (dollars in millions):”

“Assuming the merger is completed on November 2, 2026, we will operate as a combined company, and the guidance above will no longer apply.”

Source: Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the SUPN forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and diluted EPS of Supernus Pharmaceuticals, each as first reported in that quarter's release. Revenue includes ZURZUVAE collaboration revenue from July 31, 2025, when Supernus closed its acquisition of Sage Therapeutics.

We do not hold a confirmed date for Supernus Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Supernus Pharmaceuticals had total revenues of $226.8 million in Q3 2026, up 18% from $192.1 million. Net product sales were $178.6 million, collaboration revenue from ZURZUVAE $41.7 million and royalty, licensing and other revenues $6.5 million. Supernus markets its products only in the United States. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026; Supernus Pharmaceuticals Form 10-Q, Q3 2026, Oct 29, 2026)

Supernus counts four growth products, Qelbree, GOCOVRI, ZURZUVAE and ONAPGO, which together brought in $192.2 million, up 29%. Qelbree, its ADHD treatment, grew 12% to $90.8 million, mainly on volume, with IQVIA prescriptions of 282,887, up 18%. GOCOVRI reached an all-time high of $42.6 million, up about 4%, and ONAPGO, for advanced Parkinson's disease, was $17.1 million against $6.8 million. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

ZURZUVAE came with the acquisition of Sage Therapeutics on July 31, 2025, so the year-ago quarter included only two months of it. The $41.7 million is 50% of the net revenues Biogen records for ZURZUVAE, and Biogen reported US sales up approximately 53%. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

Older products continue to decline under generic competition: Oxtellar XR fell 34% to $8.0 million and APOKYN 38% to $6.5 million, while Trokendi XR was $10.2 million. Most product sales go through wholesalers and specialty pharmacies, and three customers, Cencora, Cardinal Health and McKesson, each accounted for more than 15% of total product revenue in 2025 and together for more than 76%. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026; Supernus Pharmaceuticals Form 10-K, 2025, Mar 2, 2026)

Supernus Pharmaceuticals earned $0.35 per diluted share under GAAP in Q3 2026, on net earnings of $20.9 million, against a loss of $0.80 per share, or $45.1 million, a year earlier. Supernus does not report an adjusted EPS figure; its main non-GAAP measure is adjusted operating earnings, $55.2 million against $41.9 million. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

Operating earnings were $21.2 million, against a $60.2 million operating loss. Supernus put the change down to higher revenues and lower selling, general and administrative expenses, $128.1 million against $179.7 million, because the year-ago quarter carried acquisition-related costs for Sage. Amortization of intangible assets was $23.2 million, and the quarter included $1.5 million of impairment charges; the first nine months carried $56.5 million. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

Income tax expense was $1.8 million, a 7.9% effective tax rate, against a benefit of $12.8 million a year earlier. Diluted weighted average shares were 59,471,021. (Supernus Pharmaceuticals Form 10-Q, Q3 2026, Oct 29, 2026; Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Supernus Pharmaceuticals gave a stand-alone full-year outlook with Q3 2026 results, raising 2026 total revenues guidance to $875 million to $900 million from $860 million to $890 million, with adjusted operating earnings of $160 million to $180 million. It said the guidance would no longer apply once the merger closed and Supernus operated as part of the combined company. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

The merger with Indivior was approved by shareholders of both companies on October 15, 2026, and closed on November 2, 2026. Supernus said the combined company, Supernus, Inc., is expected to realize $125 million in annual cost synergies, and that it would begin trading under SUPN on November 3, 2026. (Supernus Pharmaceuticals Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Supernus Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Supernus Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SUPN is on is SUPN a buy or a sell?, what analysts expect next is on the SUPN forecast, and what the company does is on the Supernus Pharmaceuticals (SUPN) stock page.

Every number on this page can be traced to a document Supernus Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.